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MaBACKGROUND Atrial ﬁbrillation (AF) is the most common sustained cardiac arrhythmia, yet current pharmacological
treatments are limited. Serine/threonine protein phosphatase type-1 (PP1), a major phosphatase in the heart, consists
of a catalytic subunit (PP1c) and a large set of regulatory (R)-subunits that confer localization and substrate speciﬁcity
to the holoenzyme. Previous studies suggest that PP1 is dysregulated in AF, but the mechanisms are unknown.
OBJECTIVES The purpose of this study was to test the hypothesis that PP1 is dysregulated in paroxysmal atrial
ﬁbrillation (PAF) at the level of its R-subunits.
METHODS Cardiac lysates were coimmunoprecipitated with anti-PP1c antibody followed by mass spectrometry–based,
quantitative proﬁling of associated R-subunits. Subsequently, label-free quantiﬁcation (LFQ) was used to evaluate
altered R-subunit–PP1c interactions in PAF patients. R-subunits with altered binding to PP1c in PAF were further studied
using bioinformatics, Western blotting (WB), immunocytochemistry, and coimmunoprecipitation.
RESULTS A total of 135 and 78 putative PP1c interactors were captured from mouse and human cardiac lysates, respec-
tively, including many previously unreported interactors with conserved PP1c docking motifs. Increases in binding were found
between PP1c and PPP1R7, cold-shock domain protein A (CSDA), and phosphodiesterase type-5A (PDE5A) in PAF patients,
with CSDA and PDE5A being novel interactors validated by bioinformatics, immunocytochemistry, and coimmunoprecipita-
tion. WB conﬁrmed that these increases in binding cannot be ascribed to their changes in global protein expression alone.
CONCLUSIONS Subcellular heterogeneity in PP1 activity and downstream protein phosphorylation in AF may be
attributed to alterations in PP1c–R-subunit interactions, which impair PP1 targeting to proteins involved in electrical
and Ca2þ remodeling. This represents a novel concept in AF pathogenesis and may provide more speciﬁc drug targets
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CSDA = cold-shock domain
protein A
HF = heart failure
I-1 = protein inhibitor 1
I-2 = protein inhibitor 2
LFQ = label-free quantiﬁcation
MS = mass spectrometry
PAF = paroxysmal atrial
ﬁbrillation
PDE5A = phosphodiesterase
type-5A
PP = protein phosphatase
PP1 = serine/threonine protein
phosphatase type-1
PP1c = PP1 catalytic subunit
R-subunit = regulatory subunit
WB = Western blot
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164A trial ﬁbrillation (AF) is the most com-mon sustained cardiac arrhythmia.Although current drugs improve the
functional capacity and quality of life,
many are proarrhythmic and some increase
mortality (1), pointing to a lack in the under-
standing of AF pathogenesis. Various mecha-
nisms contribute to structural, electrical, and
Ca2þ-handling remodeling in AF, which pro-
vide a platform for AF pathogenesis (2,3).
Recent studies have revealed that abnormal
phosphorylation levels of various ion chan-
nels and Ca2þ transporters are causally associ-
ated with AF development (2,4–6). Although
several studies have implicated enhanced
CaMKII activity as a potential cause of
increased protein phosphorylation in AF
(2,7), it has remained unclear why there is
great heterogeneity in protein phosphoryla-
tion in AF (2,5,6).SEE PAGE 174Protein phosphatases (PPs) play a key role in
regulating the phosphorylation level of ion channels
and Ca2þ-handling proteins in the heart (6). Serine/
threonine protein phosphatase type-1 (PP1) is a major
PP that is expressed ubiquitously in the heart where it
has a wide range of cellular targets (6,8). The PP1
holoenzyme consists of a catalytic subunit (PP1c) and
a large set of close to 200 regulatory subunits
(R-subunits) (8,9). Because there are only a few
different PP1c isoforms, all of which share a high de-
gree of homology, the spatial and temporal speciﬁcity
of PP1 for different targets is largely regulated by as-
sociation with these R-subunits.
A number of studies have shown that the global
expression and activity levels of PP1 are increased in
patients with chronic AF, associated with inhomoge-
neous changes of protein phosphorylation levels
across different subcellular compartments (4–6). For
example, although the Ca2þ-release channel ryano-
dine receptor type-2 (RyR2) is hyperphosphorylated,
the L-type Ca2þ channel is hypophosphorylated in AF
patients (4,7). By contrast, another study did not ﬁnd
any changes in PP1c expression levels in samples
from patients with paroxysmal AF (PAF) (10). In
experimental AF models, both unchanged PP1c levels
with or without increased PP1c activity have been
reported (6). These apparently contradictory ﬁndings
may be due to the fact that PP1 is regulated at the
level of its R-subunits, which underlie the heteroge-
neity in protein phosphorylation patterns within
atrial myocytes.The goal of our study was to assess the importance
of PP1 R-subunits in PAF patients, because atrial
remodeling is often still limited in such patients (10).
We developed a novel proteomic method to quantify
the levels of PP1c-bound R-subunits to characterize
the full extent of the PP1-interactome in the human
atria. This unbiased approach revealed extensive
changes in the binding of various R-subunits to PP1c
in PAF patients. This ﬁnding suggests that remodel-
ing of the PP1 interactome could be one of the main
causes of subcellular heterogeneity in protein phos-
phorylation associated with AF pathogenesis. A better
understanding of these R-subunits may therefore
lead to novel classes of drugs for treating AF.
METHODS
Animal studies were performed according to pro-
tocols approved by the institutional animal care and
use committee at Baylor College of Medicine. Hu-
man right atrial appendages were collected with
patients’ written informed consent under protocols
approved by the ethics committee of the Medical
Faculty Mannheim, University Heidelberg (No.2011–
216N-MA). Experimental details are provided in the
Online Appendix. The mass spectrometry (MS) data
are available online (11).
RESULTS
IDENTIFICATION AND LABEL-FREE QUANTIFICATION
OF PP1C INTERACTORS. To study PP1 at the level of
the R-subunits, we developed a method for proﬁling
these R-subunits in an unbiased way in vivo on the
basis of label-free quantiﬁcation (LFQ) (Figure 1,
Online Appendix). We optimized the protocol using
lysates from mouse ventricles before using smaller
atrial samples from 4 sinus rhythm patients (Online
Table 1). We identiﬁed and quantiﬁed 483 and 145
proteins from mouse and human cardiac lysates,
respectively. Of these, 133 and 78 proteins were at
least 3-fold enriched with PP1c pull-down, indicative
of speciﬁc binding to PP1c (Figure 2). To date, this is
the largest number of putative PP1c interactors
identiﬁed in cardiac tissue.
Of the 133 proteins differentially enriched from
mouse hearts, 13 are known PP1 R-subunits with
a “PPP1R” designation (i.e., PP1 regulatory subunit
followed by a unique number) according to the HUGO
Gene Nomenclature Committee (orange circles in
Figure 2A) and 4 are R-subunits or interactors that do
not yet have a PPP1R designation (blue circles in
Figure 2A) (9). In addition, there are 2 other known
interactors, Pfkm and Hspb6, that fell below the 3-
fold cutoff (dotted line in Figure 2A), suggesting that
FIGURE 1 A Novel Unbiased Method for Proﬁling PP1c Interactors
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(A) Schematic showing the major methodological steps. (B) Western blot validation of
the coimmunoprecipitation of PP1c and 1 known R-subunit (PPP1R7) from mouse ven-
tricular lysates. (C) Western blot demonstrating equal efﬁciency of anti-PP1c antibody in
pulling down mouse (Mo) and human (Hu) PP1c. LC ¼ liquid chromatography; LFQ ¼ label-
free quantiﬁcation; MS/MS ¼ tandem mass spectrometry; XIC ¼ extracted-ion
chromatogram.
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165these do not, or only partially, interact with PP1c in
mouse hearts (Online Table 2). The remaining 116 are
putative interactors that were not reported previ-
ously. Similarly, of the 78 proteins identiﬁed from
human atria (Online Table 3), 7 are known PP1 R-
subunits with a PPP1R designation, 2 are R-subunits
or interactors that do not have a PPP1R designation,
and the remaining 69 are putative interactors not
previously reported (Figure 2B).
ANALYSES OF PP1C INTERACTORS. First, we ana-
lyzed the known R-subunits by determining their
relative binding to PP1c. To do so, we normalized
their LFQ intensities to their respective sequence
lengths, because a larger protein will generally be
digested into more peptides analyzable by MS,
resulting in a higher LFQ intensity (12). For the mouse
sample, the top PP1c interactors or R-subunits which
occupy the most number of PP1c molecules were
Ppp1r7, Ppp1r2, and Ppp1r11, in descending order. For
human atria, they were PPP1R7, PPP1R18, PPP1R2, and
PPP1R8 (Figures 3A and 3B). Of these, PPP1R7 and
PPP1R2 were consistently the most highly PP1c-bound
R-subunits between mouse and human. Conversely,
we did not detect PPP1R1A (or protein inhibitor-1 [I-1])
binding to PP1c, most likely because of its low abun-
dance in the heart (13) and/or the fact that I-1 only
interacts with PP1c when it is phosphorylated at T35
by PKA (8).
Next, we analyzed all the putative PP1c interactors
in terms of 3 known PP1c docking motifs: RVxF,
MyPhoNE, and SILK (14). Of the 135 PP1c interactors
identiﬁed from mouse hearts, 105 have at least 1 of
the motifs, with 53, 68, and 45 having the RVxF,
MyPhoNE, and SILK motifs, respectively (Figure 3C,
Online Table 2). Similarly, of the 78 PP1c interactors
identiﬁed from human atria, 60 have at least 1 of the
motifs, with 39, 42, and 27 having the RVxF,
MyPhoNE, and SILK motifs, respectively (Figure 3C,
Online Table 3). Of these, most have more than 1
motif, and some have all 3 motifs (Figures 3D and 3E).
In addition to bioinformatics, we further validated
our MS method in vitro by cotransfecting 3 putative
PP1c interactors, protein transport protein Sec31A
(SEC31A), valosin-containing protein (VCP), and cold-
shock domain protein A (CSDA), with PP1c in HEK293
cells. Using these samples, coimmunoprecipitation
followed by Western blot (WB) showed a speciﬁc
interaction between PP1c and these novel interactors,
conﬁrming our MS ﬁndings (Figure 4).
CHANGES IN PP1C INTERACTOME IN PAF PATIENTS.
Because PP1c expression is altered (along with other
extensive electrical and structural remodeling) in
chronic AF, but not PAF (5), samples from PAFpatients were used in this study to avoid potential
confounders. Applying our new methodology, we
discovered 3 speciﬁc alterations in the PP1c in-
teractome: PPP1R7 (1.59-fold; p ¼ 0.044), CSDA
(5.67-fold; p ¼ 0.0010), and phosphodiesterase type-
5A (PDE5A) (1.75-fold; p ¼ 0.049) all had signiﬁ-
cantly increased binding to PP1c in PAF (Figure 5,
Online Table 4). Because PPP1R7 is the top interactor
of PP1c in human atria as shown in Figure 2B with the
highest LFQ signal and Figure 3B with the largest pie
piece (43%), a 1.59-fold increase in this binding be-
tween PPP1R7 and PP1c translates to a large change
in the PP1c interactome (e.g., 43%  1.59 ¼ 68%).
Furthermore, we validated this increase in PP1c–
PPP1R7 interaction using WB as shown in Figures 6A
and 6B, even though WB detection is not nearly as
sensitive or quantitative as MS.
Bioinformatic analyses showed that PDE5A
harbored all 3 of the PP1c docking motifs (Online
Tables 2 and 3), unlike CSDA, which may bind to
PP1c through alternative means (Figure 4C) (9).
Nevertheless, CSDA does have the highest increase in
PP1c binding in PAF (Figures 5A and 5B), making it a
potential key regulator of PP1 action in PAF.
To correlate these changes in PP1c binding to global
protein levels, we performed WB and found that,
relative to PP1c’s global protein level, PPP1R7 and
CSDA are unchanged, whereas PDE5A is up-regulated
by 1.35-fold in PAF patients (p < 0.05) (Figures 6C
and 6D). This suggests increases in binding of both
PPP1R7 and CSDA to PP1c (Figure 5B) are independent
FIGURE 2 Identiﬁcation and LFQ of PP1c Interactors
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Cardiac lysates made from mouse ventricles (A) or human atria (B) were immunoprecipi-
tated with anti-PP1c versus isotype-control IgGs and analyzed by mass spectrometry. The
y-axis plots the label-free quantiﬁcation (LFQ) signals of each protein from the anti-PP1c
pull-down. The x-axis plots the ratios of the LFQ signals from the anti-PP1c pull-down over
that from the control pull-down. Proteins with a ratio >3 are considered PP1c interactors.
Proteins with an inﬁnite ratio (N) have no LFQ signals from the control pull-down. Known
PP1c interactors are labelled with their gene names, whereas the baits Ppp1ca and PPP1CA
are marked by a black circle.
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166of their global levels, which remained unchanged in
PAF (Figures 6C and 6D). By contrast, the increase in
binding between PDE5A and PP1c may be partially
attributed to the increase in PDE5A’s global level.
When PDE5A’s increase in binding (1.75-fold) is
normalized to its increase in global level (1.35-fold),
there is still a positive ratio of 1.3-fold. This suggests
that some increase in binding between PDE5A and
PP1c is independent of the increase in PDE5A’s global
level. Taken together, these ﬁndings may indicate
that although PP1 is relatively unchanged in its global
level in PAF (Figures 6C and 6D) (10), it is dysregulated
at the level of at least 3 R-subunits/interactors.TARGETING FUNCTION OF PP1C INTERACTORS. To
further validate the 2 novel PP1c interactors CSDA and
PDE5A, immunocytochemistry was performed using
isolated mouse atrial myocytes with PPP1R7 as a
positive control. We found that both CSDA and PDE5A
localized to the periphery of the isolated myocytes,
unlike PPP1R7, which stained mostly intracellularly
(Figure 7). However, all 3 colocalized with Ppp1ca
(PP1c). Of note, CSDA costained more strongly with
PPP1CA at the periphery than PDE5A, whereas the
latter costained more strongly with PPP1CA intracel-
lularly (Figure 7). To assess whether these ﬁndings
were atrial speciﬁc, we performed the same experi-
ments in isolated mouse ventricular myocytes and
found the same costaining patterns (Online Figure 1).
Together, these results suggest that each interactor
targets PP1c to distinct subcellular compartments
where PP1c may dephosphorylate different target
proteins.
To further test this hypothesis, we transfected
HeLa cells with FLAG-tagged CSDA and performed
immunocytochemistry to see how this may affect the
subcellular localization of PP1c. Figure 8 shows that
cells that were transfected with FLAG-CSDA demon-
strated a distinct PP1c staining pattern compared
with nontransfected cells or to cells transfected with
the empty vector. Speciﬁcally, the white arrows in
Figure 8 point to nuclear or perinuclear aggregations
of PP1c, which are absent without CSDA and which
colocalize perfectly with CSDA. This supports the
hypothesis that these interactors target PP1c to
distinct subcellular compartments, as summarized in
the Central Illustration.
DISCUSSION
This study provides the ﬁrst characterization of the
extensive remodeling of the PP1c interactome in
the atria of PAF patients. Using a novel proteomic
method, we found that PP1c is dysregulated in PAF
patients by altered binding to at least 3 interactors:
PPP1R7, CSDA, and PDE5A. In addition, we identiﬁed
135 and 78 PP1c interactors in vivo from mouse and
human cardiac tissues, respectively, and analyzed
them according to the most common PP1c docking
motifs, providing further insights into the mecha-
nisms by which PP1 is regulated by these R-subunits/
interactors. Taken together, our study suggests that
alterations in the PP1c interactome via R-subunits
may contribute to subcellular heterogeneities under-
lying AF pathogenesis.
COMPARISON TO PREVIOUS STUDIES ON PP1-
REGULATORY SUBUNITS IN HEART. More than
one-half of all human proteins undergo reversible
FIGURE 3 Bioinformatic Analyses of PP1c Interactors
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167phosphorylation, the dysregulation of which drives
the pathogenesis of cardiac disease (6). To balance the
action of a plethora of kinases, the limited number of
PP catalytic subunits rely on their numerous R-subunits
to convey localization and substrate speciﬁcity (8).
Because R-subunits are at the crux of deciphering PP1
regulation, studies have increasingly recognized theneed and importance of investigating individual
R-subunits (15–19). However, these studies are few
and far between, limited to speciﬁc R-subunits on the
basis of prior (biased) knowledge.
The most-studied R-subunits in the heart are two
PP1 inhibitors, PPP1R1A (I-1) and PPP1R2 (I-2), which
were investigated in the setting of heart failure (HF)
FIGURE 4 In Vitro Validation of MS Findings
Coimmunoprecipitation followed by Western blots were performed using lysates from HEK293 cells that were cotransfected with 1 of 3 pu-
tative PP1c interactors, SEC31A (A), VCP (B), and CSDA (C), and HA-tagged PP1c. SEC31A and CSDA were FLAG tagged, whereas VCP was EGFP
tagged. CSDA ¼ cold-shock domain protein A; LFQ ¼ label-free quantiﬁcation; MS ¼ mass spectrometry; SEC31A ¼ protein transport protein
Sec31A; VCP ¼ valosin-containing protein.
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168(6). To date, the functional roles of I-1 and I-2 with
respect to global PP1c activity remain controversial.
Some studies suggest that decreased I-1 or I-2 and the
correspondingly increased PP1c activity drive HF
progression (13,20–25). Others have found the oppo-
site and suggest that decreased PP1c activity nega-
tively affects the heart (26,27). All of these studies
only measured or manipulated the global levels of I-1,
I-2, or PP1c, all of which may have affected many
cellular processes and thereby confounded the
ﬁndings. A more precise way to tease apart theFIGURE 5 Comparison of Binding Between PP1c and Known or Nove
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entire interactome and identify hotspots of dys-
regulation, as we have done for PAF patients in this
study and for cyclic adenosine monophosphate
(cAMP) nodes in HF in another recent study (28). The
methodology developed in this study may be easily
adapted to study HF in both animal models and
human patients.
POTENTIAL IMPLICATIONS FOR TARGETED
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binding between PP1c and PPP1R7 in paroxysmal atrial ﬁbrillation (PAF) patients. (C and D)
Representative Western blots and quantiﬁcation showing the global protein levels of the 3
interactors (PPP1R7, CSDA, and PDE5A) relative to that of PP1c. *p < 0.05 versus
sinus rhythm (SR). Numbers in the bars indicate the numbers of patients per group.
Abbreviations as in Figures 4 and 5.
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169identiﬁed a few other PP1 R-subunits that may play
key roles in cardiac physiology and pathophysi-
ology, such as PPP1R9B (spinophilin) and PPP1R3A
(RGL), which target PP1c to RyR2 and phospho-
lamban, respectively (6,19). To the best of our
knowledge, only 6 such R-subunits had been stud-
ied in cardiomyocytes; our present study doubles
this number with validated R-subunits as summa-
rized in the Central Illustration. Furthermore, we
identiﬁed another 67 putative R-subunits from
human atria and more than 100 from mouse ven-
tricles (Figures 2 and 3, Online Tables 2 and 3). It is
highly likely that some of these novel R-subunits
target PP1c to key cardiac proteins with currently
unknown R-subunits, such as Naþ/Ca2þ ex-
changer and voltage-dependent Naþ channel
(Central Illustration) (6). Our study provides the
relative binding levels of these R-subunits to PP1c
(Figures 3A and 3B), which may be useful for future
drug design considerations.
One of the previously unappreciated R-subunits
in the heart is PPP1R7 (SDS22), which turned out
to be the most highly bound R-subunit in both
mouse ventricles and human atria (Figures 3A and 3B).
PPP1R7 is required for cell-cycle progression or
mitosis completion in yeast by targeting PP1c to
the nucleus (8,29), which is consistent with our
immunocytochemistry ﬁnding (Figure 7A, Online
Figure 1A). However, PPP1R7 is highly expressed in
the heart (Figure 6B) and is abundantly associated
with PP1c (Figures 3A and 3B). Furthermore, the
binding between PPP1R7 and PP1c is increased in PAFFIGURE 7 Colocalization of Ppp1ca (PP1c) and Its Interactors
Atrial myocytes isolated from adult mice were costained with different a
its interactors: PPP1R7 (A), CSDA (B), and PDE5A (C). Representative ima
mm. Abbreviations as in Figures 4 and 5.(Figures 5B, 6A, and 6B), yet its role in the heart is still
virtually unknown. Future studies are needed to
determine the precise role of PPP1R7 in both cardiac
physiology and pathophysiology.ntibodies to show the colocalization between PPP1CA (PP1c) and 3 of
ges were chosen from 10 to 12 cells from 2 to 3 mice. Scale bar ¼ 20
FIGURE 8 Subcellular Targeting of PP1c by CSDA
HeLa cells were transfected with either FLAG-CSDA or empty vector and costained with anti-FLAG and anti-PP1c antibodies. White arrows in
the middle panels point to nuclear or perinuclear aggregations of PP1c, which are absent without CSDA and which colocalize perfectly with
CSDA as shown in the bottom panels. Scale bar ¼ 20 mm. CSDA ¼ cold-shock domain protein A.
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170NOVEL FINDINGS AND POTENTIAL CLINICAL
IMPLICATIONS. We discovered numerous novel PP1c
interactors, 2 of which showed up-regulated binding
to PP1c in PAF (Figure 5B). CSDA is a member of the
protein family containing the highly conserved cold-
shock domain and are considered as transcriptional
and translational regulators (30,31). As such, it is
perceivable that the increase in CSDA–PP1c associa-
tion may underlie some of the transcriptional changes
observed in PAF and perhaps drive the eventual
electrical and structural remodeling in chronic AF
(32,33). However, other than one study showing by
Northern blot that CSDA is highly expressed in cardiac
muscles (34), its role in the heart is completely un-
known. Here, we found that CSDA is not only a novelPP1c interactor but that it localizes speciﬁcally to the
sarcolemma in isolated cardiomyocytes (Figure 7,
Online Figure 1). This is different from its cytoplasmic
and nuclear localization in HeLa cells (Figure 8) (34),
suggesting an additional and previously unappreci-
ated role for CSDA, particularly in the context of PAF.
PDE5A was the ﬁrst cyclic guanosine mono-
phosphate (cGMP)-selective phosphodiesterase dis-
covered, and it is expressed mainly in vascular
smooth muscle, endothelium, and ﬁbroblast. Its
expression in cardiomyocytes is controversial (35). It
is generally believed that PDE5A localizes to Z-disks.
This is consistent with our ﬁndings in isolated myo-
cytes, although we also detected a signiﬁcant level at
the sarcolemma (Figure 7C, Online Figure 1) (35). In
CENTRAL ILLUSTRATION PP1c Interactome in Cardiomyocytes
Localization of novel PP1 regulatory (R)-subunits is on the basis of immunocytochemistry data (Figure 7, Online Figure 1) and previous studies that used noncardiac
tissues. Online Table 5 contains the deﬁnitions of the abbreviations used in the Central Illustration.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
interactome of PP1 is dysregulated in patients with
paroxysmal atrial ﬁbrillation at the level of protein–
protein interaction between the PP1 catalytic subunit
and its regulatory subunits. It is now possible to study
the PP1 interactome directly from human cardiac
tissues.
TRANSLATIONAL OUTLOOK: Clinical studies of
PP1 in atrial ﬁbrillation and other cardiac disorders
might allow targeting of molecular sites of
dysregulation for the development of novel thera-
peutic strategies.
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172cardiac hypertrophy and HF, PDE5A is up-regulated
to reduce cGMP and PKG activity, which are associ-
ated with oxidative stress (35). In our study, we also
detected both a global up-regulation as well as an
increased binding to PP1c in PAF (Figures 5B, 6C,
and 6D), similar to HF. On the other hand, another
study suggested that PDE4’s activity on cAMP is
protective against atrial arrhythmia and showed that
it decreases with age and in chronic AF patients (36).
The fact that PDE5A is up-regulated both globally and
in association with PP1c may point to a compensatory
mechanism early in AF pathogenesis.
STUDY LIMITATIONS. This study is limited by the
sample size of the atrial biopsies and by inherent
variability among the patients. Consequently, we
were not able to identify and quantify as many inter-
actors as we did with mouse samples. The inherent
variability in these samples may have masked the
subtler, but potentially important, changes in some of
the PP1c interactors. This study is also limited by the
number of samples/patients used for each of the MS
and biochemical experiments, and this diminished
our overall ability to detect small changes and
increased the probability of false positives. Future
studies with larger sample sizes are needed to conﬁrm
our ﬁndings. Finally, the sinus rhythm and PAF pa-
tients are not perfectly matched in terms of age and
sex although the differences are not statistically sig-
niﬁcant (p > 0.05) (Online Table 1).
CONCLUSIONS
In this study, we demonstrated that PP1 is dysregu-
lated in PAF at the level of protein–protein interaction
with R-subunits that modify PP1 enzymatic activity
and/or subcellular targeting. We identiﬁed 3 major
alterations in the PP1c interactome that may play a
role in AF pathogenesis. In addition, we developed a
novel, powerful technique for capturing and quanti-
fying the PP1c interactome directly from cardiac tis-
sues. This technique enabled us to identify 135 and78 PP1c interactors in vivo from mouse ventricles and
human atria, respectively. Overall, we present a rich
dataset that may open up new avenues of research
toward the understanding of both cardiac physiology
and AF pathogenesis.
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tables, and a ﬁgure, please see the online
version of this paper.
